Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 5, 2004, Pages 66-69

  Di Filippo, Franco ^a   Cavaliere, F ^a   Anza M ^a   Garinei, R ^a   Botti, C ^a   Perri, P ^a   Di Angelo, P ^a   Patrizi, V ^a   Di Filippo, S ^a   Visca, P ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Doxorubicin; Liposomal doxorubicin; Soft tissue limb sarcoma; TNF

Indexed keywords

DOXORUBICIN; LIPOSOME; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG DOSE REGIMEN; EDEMA; ERYTHEMA; FEMALE; HUMAN; HYPERTHERMIC ANTIBLASTIC PERFUSION; HYPERTHERMIC THERAPY; LIMB PERFUSION; LIMB TUMOR; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SOFT TISSUE SARCOMA; SYSTEMIC DISEASE; TEMPERATURE; TUMOR NECROSIS; TUMOR VOLUME;

EID: 19944427489     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2004.11782389     Document Type: Conference Paper

References (13)

1. Di Filippo F, Calabrò AM, Cavallari A, et al. The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg 1988;12(3):332-8.
2. Krementz ET. Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next? Cancer 1986;57(3):416-32.
3. Stehlin JS, Giovannella BC, Gutierrez AE, et al. 15 years' experience with hyperthermic perfusion for treatment of soft tissue sarcoma and malignant melanoma of the extremities. Front Radiat Ther Oncol 1984;18:177-81.
4. Di Filippo F, Rossi CR, Vaglini M et al. Hyperthermic antiblastic perfusion with alpha tumor necrosis factor and doxorubicin for the treatment of soft tissue limb sarcoma in candidates for amputation: results of a Phase 1 Study. J Immunother 1999;22(5):407-14.
5. Gabison A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokilled 2003;92:419-36.
6. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reaction. Eur J Cancer Cin Oncol 1982 Oct;18(10):905-10.
7. th Annual Meeting of the North American Hyperthermia Group. March 18-22,1989, Seattle, WA, 1989:34.
8. Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987;47(9):2403-6.
9. Niitsu Y, Watanabe N, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M, Urushizaki I: Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res 1988;48(3):654-7.
10. Di Filippo F, Garinei R, Anzà M et al. Doxorubicin in Isolated Limb Perfusion in the Treatment of Advanced Limb Soft Tissue Sarcoma. J Exp Clin Cancer Res 2003;22(4):81-87.
11. Ten Hagen TL, Van der Veen, Seynhaeve AL, van Tiel ST, Eggermont AM. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and Synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int J Cancer 2000;87(6):829-37.
12. Brouckaert P, Takahashi N, van Tiel ST, et al. Tumor necrosis factor-alpha augmented tumor response in B16 BL6 melanoma-bearing mice treated with stealth liposomal doxorubicin (Doxil) correlates with altered Doxil Pharmacokinetics Int J Cancer 2004;109(3):442-8.
13. Ten Hagen TL, Hoving S, Ambagtsheer G, van Tiel ST, Eggermont AM. Lack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats. Br J Cancer 2004 May 4;90(9):1830-2.